Walgreen's (NYSE:WAG) most recent earnings report shows a company that is still the envy of an industry from an operational standpoint, but suffering through a period of slow growth, uncertain prospects and tough comparisons.

IN PICTURES: 20 Tools For Building Up Your Portfolio

For its fiscal third quarter, the company posted $463 million in net income, or $0.47 per share, down 11% from a year ago. Total sales were up 6% year over year, to $17.2 billion, of which over 65% comes from prescription sales.

There were some charges pushing down on earnings in the third quarter, including four cents for the elimination of Medicare Part D subsidies and two cents for the acquisition of NY-based Duane Reade drug stores.

There was little to be excited about in the report, as evidenced by the 7% drop in Walgreen shares on Tuesday. To be fair, comparisons were tough versus one year ago, when H1N1 fears ruled the land and sent customers flocking to the drug store aisles. (For related reading, check out Measuring The Medicine Makers.)

Competition, Economy & Health Care Reform Loom
In the standalone field of retail drug stores, Walgreen still gets it done better than its peers. Gross margins were up year ago despite the weak economy, and stand at a healthy 27.6%, much better than rival CVS Caremark (NYSE:CVS) at 20%. Rite Aid (NYSE:RAD) looks like a similarly smooth operator with 26% gross margins, but the picture falls apart further down the income statement - Rite Aid has been posting net losses since way back when the economy was on solid footing.

The critical same-store sales measure is positive at Walgreen, but just barely. Pharmacy comps were up 0.7%, while "front-end" sales were up 0.1%. CVS grew pharmacy comps faster (3.7%) in their most recent quarter, but they have the benefit of the pharmacy benefits management (PBM) business to drive sales.

Meanwhile all the pharmacy companies - including burgeoning players like Wal-Mart (NYSE:WMT) and Costco (Nasdaq:COST) - complain of difficulties with pharmacy reimbursements, a trend that's certain to continue as healthcare reform shakes out in the coming quarters.

The Bottom Line
Walgreen shares have underperformed the S&P 500 by about 20% this year after closing out 2009 on a tear. While the drop is understandable given all the unknowns surrounding the industry -the stock market despises the unknown - Walgreen remains the top operator in the space. Their balance sheet is pristine, the stock sports a 2% yield, and prospects for the entire industry should perk up nicely in 2011 when a slew of new generics will hit the shelves.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    How Toyota Succeeds at Home and Abroad (TM)

    Japan's biggest car manufacturer is also one of North America's biggest, delighting shareholders with its high profit margins.
  2. Stock Analysis

    Starbucks: Profiting One Cup at a Time (SBUX)

    Starbucks is everywhere. But is it a worthwhile business? Ask the shareholders who've made it one of the world's most successful companies.
  3. Stock Analysis

    How Medtronic Makes Money (MDT)

    Here's the story of an American medical device firm that covers almost every segment in medicine and recently moved to Ireland to pay less in taxes.
  4. Investing News

    Latest Labor Numbers: Good News for the Market?

    Some economic numbers are indicating that the labor market is outperforming the stock market. Should investors be bullish?
  5. Investing News

    Stocks with Big Dividend Yields: 'It's a Trap!'

    Should you seek high yielding-dividend stocks in the current investment environment?
  6. Investing News

    Should You Be Betting with Buffett Right Now?

    Following Warren Buffett's stock picks has historically been a good strategy. Is considering his biggest holdings in 2016 a good idea?
  7. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  8. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  9. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  10. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center